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Abstract 
Rationale:
RSV bronchiolitis causes significant infant mortality. Bronchiolitis is characterised by airway 
epithelial cell (AEC) death, however the mode of death remains unknown.
Objectives:
To determine whether necroptosis contributes to RSV bronchiolitis pathogenesis via high 
mobility group box 1 (HMGB1) release.
Methods:
Nasopharyngeal samples were collected from children presenting to hospital with acute 
respiratory infection. Primary human AECs and neonatal mice were inoculated with RSV and 
murine pneumovirus respectively. Necroptosis was determined via viability assays and 
immunohistochemistry for receptor-interacting protein kinase-1 (RIPK1), mixed lineage 
kinase domain-like protein (MLKL) and caspase-3. Necroptosis was blocked using 
pharmacological inhibitors, and RIPK1 kinase-dead knock-in mice.
Measurements and Main Results:
HMGB1 levels were elevated in nasopharyngeal samples of children with acute RSV 
infection. RSV-induced epithelial cell death was associated with increased pRIPK1 and 
pMLKL, but not active caspase-3 expression. Inhibition of RIPK1 or MLKL attenuated RSV- 
induced HMGB1 translocation and release, and lowered viral load. MLKL inhibition 
increased active caspase-3 expression in a caspase-8/9-dependent manner. In susceptible 
mice, Pneumovirus infection up-regulated RIPK1 and MLKL expression in the airway 
epithelium at 8-10 days post infection; coinciding with AEC sloughing, HMGB1 release, and 
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neutrophilic inflammation. Genetic or pharmacological inhibition of RIPK1 or MLKL 
attenuated these pathologies, lowered viral load, and prevented type-2 inflammation and 
airway remodeling. Necroptosis inhibition in early-life ameliorated asthma progression 
induced by viral or allergen challenge in later-life.
Conclusions:
Pneumovirus infection induces AEC necroptosis. Inhibition of necroptosis may be a viable 
strategy to limit the severity of viral bronchiolitis and break its nexus with asthma.
Word count: 250
MeSH key words: Bronchiolitis, asthma, MLKL, Pneumovirus, necroptosis
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Introduction
Respiratory syncytial virus (RSV)-induced bronchiolitis is associated with significant 
mortality worldwide (1). Additionally, severe RSV bronchiolitis in infancy is associated with 
subsequent airways disease including asthma (2-4). In the absence of an approved vaccine for 
RSV, new treatments that effectively manage and reduce RSV-associated pathogenesis are 
urgently needed. Pathologically, severe bronchiolitis is characterised by neutrophilic 
inflammation, mucus hypersecretion, and airway epithelial cell (AEC) sloughing (5, 6). 
These dead epithelial cells, together with a viscous exudate, can form dense plugs in the 
bronchiolar lumen that impede breathing (6, 7). Despite this, the prevailing view is that AEC 
death is a beneficial defense mechanism, limiting viral spread.
Host defense to viral infection depends on the activation of innate pattern recognition 
receptors, which induce the production of antiviral cytokines such as type I and III IFNs. In 
turn, these cytokines initiate the antiviral state to restrict virus replication and spread, and 
promote the activation of NK cells and cytotoxic T lymphocytes (CTLs) that ultimately clear 
the virus by inducing apoptotic death of infected cells (8). Genetic and/or environmental 
factors that perturb the successful coordination of this response predispose toward severe 
RSV bronchiolitis (9-11). To model the immunopathology and sequelae, we developed a 
preclinical gene-environment model by inoculating interferon regulatory factor 7 (IRF7)-
deficient mice with PVM, a mouse Pneumovirus and homolog of RSV. As a consequence of 
impaired antiviral immunity, these mice develop severe epithelial sloughing, leading to 
HMGB1 release and neutrophilic inflammation in early-life, and are predisposed to asthma in 
later-life (unpublished observations). Critically, HMGB1 neutralisation ablated all of these 
events.
HMGB1 is a chromatin-binding protein that can be released into the extracellular space to 
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function as a pro-inflammatory cytokine. As a consequence, its release and activation state is 
highly controlled. Cellular mechanisms known to regulate HMGB1 release include vesicular 
transport, inflammasome activation, necrosis, and necroptosis (12-15). This recently 
identified form of programmed cell death is initiated by the formation of a multi-protein 
complex termed the necrosome (16), which typically contains phosphorylated RIPK1 
(pS166) and pRIPK3, leading to the phosphorylation of MLKL (13, 14, 17, 18). In contrast to 
apoptosis, necroptosis most commonly elicits a pro-inflammatory response, in keeping with 
its role in mediating HMGB1 release, and can delay viral clearance (19). This led us to 
question the current dogma that the induction of AEC death during RSV bronchiolitis serves 
to restrict virus spread and limit host immunopathology. Specifically, we interrogated the 
mode of RSV-associated AEC death and downstream HMGB1 release using human and 
mouse primary AECs in culture. To support our in vitro findings, we evaluated the 
mechanism of AEC sloughing and HMGB1 release, and the effect of necroptosis inhibition, 
in our preclinical model of severe viral bronchiolitis and later experimental asthma.
Materials and Methods.
Human subjects and nasopharyngeal samples.
Samples were prospectively collected from 2-year-old children (IQ range 1.25 to 3.86) 
presenting with acute respiratory infection to the Princess Margaret Hospital, Perth. Ethical 
approval was obtained from the ethics committees of Princess Margaret Hospital for Children 
(1673/EP), the South Metropolitan Area Health Service, and the Western Australian Aboriginal 
Health Information and Ethics Committee. All samples were frozen at -80oC prior to the 
measurement of HMGB1 by ELISA (Chondrex, Redmond, WA, US). The presence of 
respiratory viruses was tested by polymerase chain reaction (PCR) assay.
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hAEC culture and treatment
Human AECs from healthy paediatric (age 2-3 years) donors (ID 28195, 28563, 28385, and 
29055) were obtained commercially (Lonza). Purified RSV A2 stocks were prepared as 
previously described (20). Non-differentiated (submerged) or air-liquid interface (ALI)- 
differentiated AECs were grown and infected with RSV as previously described (21, 22). One 
hour prior to RSV infection, the cells were pre-treated with a pRIPK1inhibitor (Necrostatin 
1s; Nec-1s, 2.2 µM; Biovision) (23), which reduces RIPK1 phosphorylation, an MLKL 
inhibitor (necrosulfonamide; NSA; 10 µM; Merck) (24), which prevents MLKL translocation 
to the plasma membrane, a caspase-9 inhibitor (Z-LEHD-FMK; 2 µM; Biovision), and/or a 
caspase-8 inhibitor (Z-IETD-FMK; 2 µM; Biovision). After 12 or 24 hours, supernatant was 
collected and stored at -80°C, and the cells fixed with neutral buffered 10% formalin solution 
(Sigma) for 15 mins.
Murine airway epithelial cell culture
Murine airway epithelial cells were cultured as described (21, 25). The cells were inoculated 
with PVM (MOI of 0.5) or vehicle, then fixed with formalin 8 hours later. In some 
experiments, cells were pre-treated for 30 minutes with GW80 (2 µM; SYNkinase) (26) or 
the RIPK1 inhibitor GSK’963 (4.3 mM; GSK)(27).
Mouse strains and treatments
All studies were approved by the University of Queensland and QIMR Berghofer Animal 
Care and Ethics Committees. RIPK1 K45A/K45A mice (GlaxoSmithKline) and IRF7-/- mice 
(provided by Dr. Tadatsugu Taniguchi, University of Tokyo), were rederived and crossed to 
generate IRF7-/- RIPK1 K45A/K45A. Wild-type (WT), IRF7-/-, RIPK1 K45A/K45A, and IRF7-/- 
RIPK1K45A/K45A mice (all C57BL/6 background) were bred in SPF animal houses at the 
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University of Queensland and at QIMR Berghofer MRI. At postnatal day 7, neonatal mice 
were inoculated (intranasal route) with 2 plaque-forming units (PFU) of PVM (J3666 strain) 
in 10 µl of vehicle (10% fetal calf serum in DMEM media), as described previously (21). In 
some experiments, the mice were re-inoculated with 100 PFU of PVM at 42 days post 
infection (dpi) or given 4 weekly inoculations of 1 µg of cockroach allergen extract (CRE; 
GREER) commencing at 42 dpi. Control mice received vehicle alone. To inhibit necroptosis, 
WT and IRF7-/- neonatal mice were injected (i.p. route) with Nec-1s (6 mg/kg at 5 and 7 dpi; 
Biovision) (23), GSK’963 (10 mg/kg, twice daily from 5 dpi; GSK) (27), or GW806742X 
(GW80, 50 µg/kg at 7 and 9 dpi; SYNkinase). For analyses at 7 dpi, mice were treated with 
GW80 at 5 dpi. BALF collection occurred as described previously (28).
Bronchoalveolar lavage fluid (BALF) collection, flow cytometry, cytokine analysis, 
immunohistochemistry and immunofluorescence, quantitative real time PCR, ALI 
culture and treatment.
Details are provided in the online supplement.
Statistical analysis
Statistical analyses were performed using GraphPad Prism v.6.0 and JMP Pro (v 15.0, SAS 
Institute, Cary, NC). Student’s t-test or the Mann-Whitney t-test were used for comparing 2 
groups. When more than two groups were compared, data were analyzed using a one- or 
two-way ANOVA with Dunnett’s or Sidak’s post hoc test to compare to a control group, 
respectively. The specific procedure is annotated for each figure.  Although  our decision to 
use parametric analyses is based on longer term experience with the specific assays producing 
normal residuals (29), we examined the residuals (N≥16) from each analysis for normality 
using the Shapiro-Wilks test and normal quantile plots as a quality control measure. In all but 
one case normality was supported. In figure 2C there was one outlier in the RSV condition, 
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which, when excluded yielded approximate normality. The results for this analysis were 
similar whether the outlier was excluded or not, or using robust alternatives (Kruskal-Wallis 
test with Dunn’s post hoc test).  All analyses involving the four human donor samples were 
also re-analysed using mixed effects models with donor as a random effect.
Differences in HMGB1 expression in nasopharygeal samples was analysed using a Mann-
Whitney t test as this assay tends to generate skewed data.  We annotated statistically 
significant results with * or #, P <0.05; ** or ##, P <0.01; *** or ###, P <0.001.
Results
RSV infection of primary human AECs activates RIPK1 and MLKL.
To address whether RSV infection is associated with increased levels of HMGB1, we 
obtained nasopharyngeal samples from young children presenting to hospital with acute 
respiratory infection. HMGB1 levels were significantly greater in the children infected with 
RSV as compared to an infection with a different respiratory virus (Fig. 1A). We then 
obtained human primary airway epithelial cells (hAECs) obtained from healthy children to 
assess mechanisms of HMGB1 release in vitro (30). RSV (MOI 1) significantly increased 
nuclear-to-cytoplasmic translocation of HMGB1 and extracellular HMGB1 release at 24 hr 
post infection (hpi; Fig. 1B-C). This was associated with elevated release of dsDNA and 
LDH, and loss of plasma membrane integrity, shown by increased propidium iodide staining 
(PI), all indicative of cell death (PI; Fig. 1D). To explore the mode of cell death, we stained 
the AECs for active caspase-3 (CC3), annexin V, phosphorylated (p)RIPK1 (Ser166), and 
pMLKL (Ser358). The negative immunoreactivity for CC3 and Annexin V, and positive 
immunoreactivity for pRIPK1 and pMLKL suggested the cells were undergoing necroptosis, 
not apoptosis (Fig. 1E-G). These data were re-analysed using random effects models to 
account for possible donor effects. These analyses yielded the same conclusions and donor 
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effects were not substantial or significant (data not shown).
Pharmacological inhibition of RIPK1 or MLKL attenuates RSV-induced HMGB1 
release.
To assess whether necroptosis actively contributes to RSV-induced HMGB1 release at 24 
hpi, we treated hAECs with Necrostatin-1s (Nec-1s) or necrosulfonamide (NSA) to inhibit 
RIPK1 and MLKL respectively (31, 32). Nec-1s treatment significantly decreased pRIPK1+ 
and pMLKL+ cells, whereas NSA, acting downstream of pRIPK1, significantly decreased the 
fraction of pMLKL+ cells (Fig. 2A). The MLKL inhibitor increased CC3+ cells (Fig. 2A, 
bottom right panel) and annexin-V+ cells (Fig. 2B). Increased CC3 expression was ablated 
when both caspase-8 and 9 were inhibited, suggesting both intrinsic and extrinsic apoptosis 
pathways are induced upon MLKL inhibition (Supplemental Fig. E1A). RIPK1 or MLKL 
inhibition significantly decreased translocation and release of HMGB1 (Fig. 2C-D), and 
lowered viral load (Fig. 2E, Supplemental Fig. E1B). Simultaneous inhibition of MLKL, 
caspase-8 and 9 attenuated this protective effect, implicating a role for both intrinsic and 
extrinsic apoptosis pathways in viral clearance (Supplemental Fig. E1A). Lower viral burden 
after MLKL inhibition was not associated with increased type I or type III IFN expression 
(Supplemental Fig. E1C-E). These phenotypes were replicated in air-liquid interface (ALI) 
differentiated AECs (Supplemental Fig. E2). Collectively, these data suggest that necroptosis 
contributes to HMGB1 release and viral persistence.
Pneumovirus infection induces necroptotic cell death in the airway epithelium in vivo.
We next sought to determine whether necroptosis is pathogenic in a high-fidelity preclinical 
model of viral bronchiolitis. As a natural mouse pathogen, pneumonia virus of mice (PVM) 
can be administered at low doses, allowing for the study of host-pathogen interactions as the 
virus replicates (21, 28, 33-36). We previously demonstrated that PVM infection of IRF7-/-
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mice leads to severe viral bronchiolitis, with peak viral burden occurring at 7 dpi, followed 
by neutrophilic inflammation, extensive epithelial sloughing, and elevated HMGB1 levels in 
the airway lumen at 10 and 14 dpi (unpublished observations). As epithelial sloughing is 
indicative of cell death, and necroptosis has been linked to HMGB1 release (12, 37), we first 
sought to determine the temporal pattern of gene and protein expression for cell death 
associated caspases and kinases. At the gene level, using whole lung samples, we did not 
detect a significant increase in caspase-3 expression in either the WT or IRF7-/- mice 
following PVM infection (Fig. 3A). In contrast, there was a significant increase in RIPK1, 
MLKL and RIPK3 gene expression in IRF7-/- compared to WT littermates (Fig. 3A). A 
similar phenotype was observed regarding protein expression: pRIPK1 (Ser166) and MLKL 
expression was elevated in the airway epithelium at 8, 9 and 10 dpi (Fig. 3B). This was 
associated with elevated levels of dsDNA, LDH, and TNFα in the airway lumen 
(Supplemental Fig. E3A). MLKL expression co-localised with pRIPK1 in AECs (Fig. 3B), 
was typically expressed in cells with an abnormal (diffusely stained) nuclei (Supplemental 
Fig. E3B) and was predominantly observed at the apical surface (Supplemental Fig. E3C), 
consistent with other reports (38). Moreover, we observed MLKL immunoreactivity in 
sloughed AECs in the airway lumen, suggesting a link between necroptosis and epithelial 
denudation (Supplemental Fig. E3D). PVM SH gene and PVM protein levels were greater in 
IRF7-/- compared to WT mice, and peaked at 4 and 7 dpi respectively (Fig. 3C), the period of 
necroptosis onset (Fig. 3B). At both 7 and 10 dpi, the majority of MLKL+ AECs were 
immunoreactive for PVM (Supplemental Fig. E3E). Notably, increasing the viral inoculum to 
100 PFU in WT mice increased the fraction of pRIPK1/MLKL+ AECs to similar levels as 
observed in IRF7-/- mice infected with 2 PFU (Supplemental Fig. E3F), suggesting that 
necroptosis is influenced by viral load and can occur in immunocompetent mice. Collectively, 
these data suggest that Pneumovirus infection leads to necroptosis, and that this is heightened 
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when innate antiviral immunity is impaired.
Pharmacological inhibition of RIPK1 or MLKL decreases bronchiolitis-associated 
immunopathology.
To evaluate whether necroptosis contributes to the pathogenesis of acute bronchiolitis, we 
treated WT and IRF7-/- mice with the RIPK1 inhibitor, Nec-1s or the MLKL inhibitor, GW80 
(NSA does not inhibit murine MLKL), starting at 5 dpi (Fig. 4A). Pharmacological inhibition 
of RIPK1 or MLKL significantly decreased the fraction of pRIPK1 and MLKL positive 
AECs at 10 dpi in the IRF7-/- infected mice. Inhibition of MLKL, but not RIPK1, increased 
the number of CC3 expressing AECs (Fig. 4B-C), suggesting a switch in cell death modality. 
Treatment with either inhibitor significantly decreased viral burden (7 dpi; Fig. 4D), an effect 
that was not related to changes in IFN-// expression (data not shown), and ameliorated 
neutrophilic inflammation (Fig. 4E). This was associated with a decrease in epithelial 
sloughing, as well as LDH, dsDNA but not TNFα expression (10 dpi; Fig. 4E-F, 
Supplemental Fig. E4A). RIPK1 or MLKL inhibition was associated with reduced 
cytoplasmic-HMGB1+ AECs and extracellular HMGB1 (Fig. 4G), while only MLKL 
inhibition decreased IL-33 levels in the airway lumen (Supplemental Fig. E4B), suggesting 
that the pRIPK1/MLKL necrosome regulates epithelial cell death and subsequent HMGB1 
release during acute Pneumovirus infection in vivo.
RIPK1 or MLKL inhibition prevents the development of type-2 inflammation.
We next assessed the effect of Nec-1s or GW80 treatment on the induction of type-2 
inflammation in PVM-infected IRF7-/- mice. Similar to our previous findings in other 
immunocompromised mice (35, 36), IL-13-producing group 2 innate lymphoid cells (ILC2s), 
eosinophilic inflammation, airway smooth muscle (ASM) remodeling and mucus 
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hypersecretion were all elevated in IRF7-/- compared to WT mice (Fig. 5). This type-2 
inflammatory response was significantly attenuated following treatment with Nec-1s or 
GW80 (Fig. 5). These findings were validated when mice were treated with GSK’963 
(Supplemental Fig. E5), another inhibitor of RIPK1 (39), further implicating a role for 
necroptosis in promoting Pneumovirus-associated type-2 inflammation.
RIPK1 kinase dead knock-in mice are protected from viral bronchiolitis.
As pharmacological inhibitors can elicit off-target effects, we sought to confirm our findings 
using RIPK1K45A/K45A transgenic mice in which the scaffold function of RIPK1 is preserved 
and the kinase activity of RIPK1 is ablated (40). As expected, pRIPK1 and MLKL expression 
was attenuated in PVM-infected IRF7-/- RIPK1K45A/K45A Tg mice compared to IRF7-/- 
littermate controls (Fig. 6A). Genetic inactivation of RIPK1 enzymatic activity conferred 
protection against severe viral bronchiolitis (high viral load, neutrophilic inflammation, AEC 
sloughing; Fig. 6B-C), alarmin release (HMGB1; Fig. 6D), type-2 inflammation (ILC2s, 
eosinophils; Fig. 6E) and airway remodeling (ASM growth, mucus hypersecretion; Fig. 6F), 
further suggesting that necroptosis is pathogenic in the context of RSV bronchiolitis.
Pneumovirus infection induces necroptosis and HMGB1 release in differentiated mouse 
AECs
To definitively show that PVM induces the release of HMGB1 from AECs in a RIPK1 kinase 
dependent manner, we next cultured primary mouse AECs from WT and RIPK1K45A/K45A Tg 
mice. As PVM does not infect undifferentiated mAECs, we differentiated the cells at air- 
liquid interface prior to inoculation. Consistent with hAECs, Pneumovirus infection increased 
pRIPK1+ and MLKL+ mAECs, in the absence of a CC3+ signal (Fig. 7A), and increased 
dsDNA in the basal media at 24 hpi (Fig. 7B). In the absence of RIPK1 kinase activity, 
pRIPK1+ and MLKL+ cells were significantly decreased (Fig.7C), as was translocation and 
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release of HMGB1 (Fig.7D). Similarly, treatment of WT mAECs with Nec-1s decreased 
HMGB1 translocation, and both Nec-1s or GW80 decreased HMGB1 release (Fig.7E). 
Consistent with the in vivo findings, CC3 was elevated in PVM-infected mAECs treated with 
the MLKL, but not the RIPK1 inhibitor (Fig. 7F).
Inhibition of pRIPK1or MLKL during severe bronchiolitis prevents progression to later 
asthma.
Severe or frequent lower respiratory infections are an independent risk factor for asthma (2- 
4). This epidemiology is captured in our preclinical model as a secondary insult promotes 
experimental asthma (35) Therefore, we hypothesised that inhibition of Pneumovirus-
associated necroptosis in early life would prevent the later development of virus- or allergen- 
induced asthma. WT and IRF7-/- mice were infected with PVM in early life and treated with 
Nec-1s or GW80 in infancy, then 6 weeks later, challenged with either PVM or exposed to 
cockroach extract (once/week for 4 weeks) to induce experimental asthma (Fig. 8A). 
Pharmacological inhibition of RIPK1 or MLKL in neonates decreased ASM remodelling, 
mucus hypersecretion, and eosinophilic inflammation in the predisposed IRF7-/- mice (Fig. 
8B-E).
Discussion
New therapies are needed to reduce the significant mortality and morbidity associated with 
RSV bronchiolitis (1). Here we show that infection with human RSV or mouse PVM induces 
necroptosis in AECs using both in vivo and in vitro model systems, and that this contributes 
to disease pathology and pathogenesis. Specifically, we show that inhibition of pRIPK1 
kinase activity or MLKL ablates RSV/PVM associated necroptosis, attenuating the release of 
the pro-inflammatory alarmin HMGB1, and downstream sequelae. In addition to improving 
viral control and ameliorating viral bronchiolitis associated immunopathology, inhibition of 
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necroptosis in infancy protected against the later development of viral and allergic 
experimental asthma.
A hallmark of severe viral bronchiolitis is the loss of airway epithelial integrity, leading to 
epithelial cell sloughing and formation of Creola bodies in the airway lumen (41). However, 
the mode of cell death has remained elusive. Using cultured human AECs, we and others 
have shown that RSV infection does not increase caspase-3/7 or caspase-9 activity, markers 
of apoptotic death (42, 43). This response may reflect the ability of RSV, via non-structural 
protein-1 and 2 and other molecules, to actively inhibit apoptosis (43-45). Here we confirm 
that RSV infection fails to induce apoptosis, and show for the first time in human primary 
AECs that RSV induces RIPK1 activation (monitored by auto-phosphorylation on Ser166) 
and MLKL-dependent loss of cell viability, indicative of necroptosis. Inhibition of pRIPK1 
kinase activity or MLKL decreased cytoplasmic translocation and release of HMGB1, and 
also decreased viral burden, suggesting that therapies which ablate epithelial necroptosis will 
exhibit dual anti-viral and anti-inflammatory activity.
To explore the contribution of necroptosis in vivo, we utilised a neonatal model of severe 
bronchiolitis that employs low dose viral infection in a genetically susceptible host (to 
simulate the gene-environment interactions that underpin disease) (35). Notably, epithelial 
sloughing, a hallmark feature of bronchiolitis, is absent in mice following inoculation with 
hRSV, even at supraphysiological doses. This likely reflects the fact that Pneumoviruses are 
host-specific (46, 47). By performing temporal studies, we show in PVM-infected neonatal 
IRF7-/- mice that necroptosis, (i) is the primary model of airway epithelial cell death during 
bronchiolitis, (ii) is initiated soon after peak viral replication, and (iii) precedes the 
development of airway remodeling and type-2 inflammation. Pharmacologic or genetic 
ablation of necroptosis decreased AEC sloughing and attenuated the pro-inflammatory 
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neutrophilic response. This prevented the development of type-2 inflammation and ASM 
remodeling in infancy and later development of experimental asthma. This was particularly 
apparent in mice treated with the MLKL inhibitor, which had a greater impact on eosinophils, 
compared to RIPK1 inhibition, suggesting either RIPK1 conveys some small protective 
functions or that MLKL is involved in cell death-independent pathways that promote type-2 
inflammation. The impetus for this study stemmed from our unpublished observations 
demonstrating that HMGB1 is highly pathogenic in the context of bronchiolitis and reports in 
the literature linking necroptosis to HMGB1 release (12, 37). We show that HMGB1 levels 
are elevated in nasopharyngeal samples of RSV infected children, and that the beneficial 
effects of inhibiting necroptosis (in vivo in mice and in vitro cultured AECs) are associated 
with a marked decrease in HMGB1 levels. Thus, our findings suggest that inhibiting 
HMGB1, through monoclonal antibody-mediated neutralisation or inhibition of necroptosis, 
will reduce the high morbidity, and potentially mortality, of severe RSV bronchiolitis. By 
ablating the onset of type-2 inflammation and ASM remodeling, necroptosis inhibitors may 
serve as primary preventatives for asthma in predisposed individuals.
In both in vitro and in vivo models, genetic or pharmacologic inhibition of RIPK1 kinase 
activity and MLKL decreased viral load. This was unexpected in the in vivo model because 
the increase in pRIPK1/MLKL at 7 dpi was not statistically significant. However, it is 
apparent from the time course studies that the upregulation and phosphorylation of 
necroptosis-associated proteins is initiated between 4 and 7 dpi, followed by a sharp increase 
at 8-10 dpi, inferring a feed-forward loop. In other investigations of necroptosis-associated 
kinases, RIPK3 was shown to limit the propagation of herpes simplex virus, influenza virus A 
and vaccinia virus (17, 48, 49), although notably this phenotype was not observed with 
influenza H7H9 infection (50). RIPK3 can contribute to both apoptosis and necroptosis, and 
is involved in pro-inflammatory cytokine production, complicating interpretations. As such, 
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even though its expression was increased in PVM-infected mice, we did not seek to assess the 
role of RIPK3 in the present study. Unlike RIPK3 deficiency, genetic deletion of MLKL did 
not affect influenza virus A replication or clearance (48). In summary, the consequence of 
necroptosis on viral pathogenesis appears to be context and virus-dependent; the latter 
potentially relating to the ability of the virus to preferentially inhibit or induce apoptosis 
and/or necroptosis.
The mechanism by which inhibition of necroptosis lowered Pneumovirus load remains 
elusive. In both the in vivo and in vitro models, inhibition of necroptosis did not lead to an 
increase in the expression of type I or type III IFNs. However, inhibition of MLKL led to a 
significant increase in the number of active caspase-3 immunoreactive epithelial cells, despite 
two different MLKL inhibitors being used. This highly reproducible phenotype was not 
apparent after RIPK1 inhibition, suggesting that the inhibition of MLKL initiates a RIPK1- 
dependent apoptotic pathway. The propensity for necroptosis over apoptosis following 
Pneumovirus infection suggests that the virus subverts apoptosis, which is well established; 
our findings suggest that blocking necroptosis either overcomes this subversion or initiates a 
different pathway to apoptosis that is not inhibited by the virus. Further studies are needed to 
reveal these molecular processes; however, we were able to implicate both intrinsic and 
extrinsic apoptosis pathways as dual inhibition of caspase-8 and -9 prevented processing of 
caspase-3 and the fall in viral load induced via MLKL inhibition.
Typically, the induction of necroptosis is achieved by sensitising cells via the use of a 
chemical agent, and consequently such studies are less physiologically relevant. A strength of 
this study is that RSV/PVM naturally induced necroptosis without the use of an apoptosis 
inhibitor, likely due to the anti-caspase activity of the virus or ablation of a necroptosis 
repressor. Multiple pro-inflammatory pathways can induce necroptosis upon viral infection, 
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including TLR, IFN or TNF receptor activation (13, 14, 18). A limitation of the current study 
is that we did not explore this specifically, however the elevated viral load, in the absence of 
increased IFNs or TNF at 7 or 8 dpi, implicates a virus-sensing pattern recognition receptor.
In summary, we demonstrate that in their host-specific setting, Pneumoviruses induce 
necroptosis in AECs, leading to release of HMGB1. Inhibition of RIPK1 kinase activity or 
MLKL ameliorates the severity of bronchiolitis by decreasing viral load and 
immunopathology, which in turn prevents the development of type-2 inflammation and 
associated ASM remodelling. Consequently, susceptibility to later asthma is lowered. Our 
findings implicate necroptosis in the pathogenies of bronchiolitis and suggest that therapeutic 
targeting of its effector kinases would ameliorate bronchiolitis severity and potentially act as 
an asthma preventative in a subpopulation of individuals whose aetiology is linked to early-
life viral infections. Further work is required to identify safe and effective ways to target this 
important pathway, a critical step in developing future RSV therapies.
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Figure legends:
Figure 1: RSV infection of primary human AECs activates RIPK1 and MLKL.
(A)HMGB1 levels assessed in nasopharyngeal samples obtained from young children 
presenting with acute respiratory infection with RSV or other respiratory viruses.
(B-G) Submerged primary human AECs were infected with RSV (MOI of 1), and HMGB1 
expression and various analyses of cell death examined at 12 and 24 hours.
(B) Representative micrographs (x400 magnification) of HMGB1 (green) in AECs. 
Quantification of cyto-HMGB1.
(C) Protein expression of HMGB1 in supernatant.
(D)Expression of dsDNA and LDH in supernatant. Quantification of PI positive AECs.
(E) Quantification of cleaved caspase-3 and annexin V positive AECs.
(F) Representative micrographs (x400 magnification) of pRIPK1 (red) in AECs. 
Quantification of pRIPK1 positive AECs.
(G)Representative micrographs (x400 magnification) of pMLKL (red) in AECs. 
Quantification of pMLKL positive AECs.
Data are representative of n = 2 experiments with four donors in each group and are presented 
as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data were 
analyzed using Mann-Whitney T test (A) or two-way ANOVA with Sidak’s post hoc test. *, 
P <0.05; **, P <0.01; ***, P <0.001 denote significance between infected and uninfected 
hAECs at each time point.
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Figure 2: Pharmacological inhibition of RIPK1 or MLKL attenuates RSV-induced 
HMGB1 release.
Submerged hAECs were pre-treated with a RIPK1 inhibitor (Nec-1s) or MLKL inhibitor 
(NSA) prior to infection with RSV (MOI of 1).
(A)Representative micrographs (x400 magnification) of pRIPK1 (red), and pMLKL (red) 
and cleaved caspase-3 (green), and quantification of pRIPK1, pMLKL and cleaved 
caspase-3 (CC3) positive AECs.
(B) Quantification of annexin V positive AECs.
(C) Quantification of cyto-HMGB1 positive AECs.
(D)HMGB1 protein expression in supernatant.
(E) Quantification of RSV positive AECs.
Data are representative of n = 2 experiments with four donors in each group and are presented 
as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data were analyzed 
by one-way ANOVA with Dunnett’s post hoc test. *, P <0.05; **, P <0.01 and ***, P <0.001 
are compared to uninfected hAECs and #, P <0.05; ##, P <0.01; ###, P <0.001 are compared 
to RSV-infected hAECs.
Figure 3: In vivo Pneumovirus infection induces necroptotic cell death in the airway 
epithelium.
Neonatal WT and IRF7-/- mice were infected with PVM (2 pfu) and cell death-related 
genes/proteins and viral load assessed over time.
(A)Lung gene expression of caspase-3, Ripk1, Mlkl and Ripk3.
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(B) Representative micrographs (x400 magnification) of cleaved caspase-3 (green), pRIPK1 
(red) and pMLKL (yellow). Quantification of pRIPK1, pMLKL and cleaved caspase-3 
(CC3) in AECs.
(C) Lung gene expression of PVM SH gene. Representative micrographs (x400 
magnification) of PVM (green) and quantification of PVM positive AECs.
Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as mean ± S.E.M.. Data were analyzed by two-way ANOVA with Sidak’s post hoc 
test. *, P <0.05; **, P <0.01; ***, P <0.001 are compared to PVM infected WT at each time 
point.
Figure 4: Inhibition of RIPK1 or pMLKL reduces alarmin release and bronchiolitis in 
IRF7-/- mice during acute viral infection.
Neonatal WT and IRF7-/- mice were infected with PVM (2 pfu) at 7 days of age. Mice were 
treated with either a RIPK1 inhibitor (Nec-1s) or MLKL inhibitor (GW80). Alarmin release 
and bronchiolitis-associated pathologies were assessed at 7 and 10 dpi.
(A)Study design.
(B) Quantification of pRIPK1 and MLKL positive AECs.
(C) Quantification of cleaved caspase-3 (CC3) positive AECs.
(D)Quantification of PVM positive AECs.
(E) AEC sloughing normalised to basement membrane length. Neutrophils in BALF.
(F) LDH and dsDNA in BALF.
(G)Quantification of cyto-HMGB1 and HMGB1 protein expression in BALF.
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Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed by two-way ANOVA with Sidak’s post hoc test. *, P <0.05; **, P <0.01 and 
***, P <0.001 are compared to untreated (diluent) WT or IRF7-/- infected mice. #, P <0.05; 
##, P <0.01 and ###, P <0.001 are compared to Nec-1s treated WT or IRF7-/- infected mice.
Figure 5: Inhibition of RIPK1 or MLKL prevents the development of type-2 
inflammation.
Neonatal WT and IRF7-/- mice were infected with PVM (2 pfu) at 7 days of age. Mice were 
treated with either a RIPK1 inhibitor (Nec-1s) or MLKL inhibitor (GW80) and markers of 
type-2 inflammation assessed at 10 dpi.
(A)Total ILC2s in lung. The number of IL-13+ ILC2s in the lung were quantified in 
4C13R/WT and 4C13R/IRF7-/- infected mice.
(B) Eosinophils in BALF.
(C) Representative micrograph (x100 magnification) and quantification of ASM.
(D)Representative micrograph (x100 magnification) and quantification of Muc5ac positive 
AECs.
Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed by two-way ANOVA with Sidak’s post hoc test.  *, P <0.05; **, P <0.01; ***, 
P <0.001 are compared to untreated (diluent) WT or IRF7-/- or 4C13R/WT or 4C13R/IRF7-/- 
infected mice. #, P <0.05; ##, P <0.01 and ###, P <0.001 are compared to Nec-1s treated WT 
or IRF7-/- infected mice.
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Figure 6: RIPK1 kinase dead knock-in mice are protected from viral bronchiolitis. 
Neonatal WT, RIPK1K45A/K45A, IRF7-/- and IRF7-/- RIPK1K45A/K45A were infected with PVM (2 
pfu) at 7 days of age. Alarmin release and bronchiolitis-associated pathologies were assessed 
at 7 and 10 dpi.
(A)Quantification of pRIPK1, MLKL and cleaved caspase-3 (CC3) positive AECs.
(B) Quantification of PVM.
(C) Neutrophils in BALF and quantification of AEC sloughing.
(D)Quantification of cytoplasmic HMGB1 and HMGB1 expression in BALF.
(E) ILC2s in lung and eosinophils in BALF.
(F) Quantification of ASM area and Muc5ac positive AECs.
Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed by one-way with Dunnett’s post hoc test. *, P <0.05; **, P <0.01; ***, P 
<0.001 are compared to IRF7-/- infected mice.
Figure 7: Murine Pneumovirus infection induces necroptosis and HMGB1 release in 
differentiated mouse AECs.
Mouse AECs were differentiated at air-liquid interface. Cells were infected with PVM and 
expression of HMGB1 and necroptosis proteins were assessed at 24 hours post infection.
(A)Representative images (x400 magnification) of cleaved caspase-3 (green), pRIPK1 (red) 
and MLKL (yellow). Quantification of cleaved caspase-3 (CC3), pRIPK1 and MLKL 
positive AECs.
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(B) dsDNA expression in basal media.
(C) Quantification of pRIPK1and MLKL positive AECs.
(D)Quantification of cyto-HMGB1 positive AECs. HMGB1 protein expression in basal 
media.
(E) Quantification of cyto-HMGB1 positive AECs. HMGB1 protein expression in basal 
media.
(F) Quantification of cleaved caspase-3 positive AECs.
Data are representative of n = 2 experiments with four to seven neonates in each group and 
are presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed using Student’s t test (A-B) or two-way ANOVA with Sidak’s post hoc test 
(C-D) or one-way ANOVA with Dunnett post hoc test (E-F). *, P <0.05; **, P <0.01; ***, P 
<0.001 are compared to uninfected mAECs (A, B, E, F) or PVM-infected RIPK1K45A/K45A 
mAECs (C-D). #, P <0.05 and ##, P <0.01 compared to PVM-infected WT mAECs.
Figure 8: Inhibition of pRIPK1 or MLKL during severe bronchiolitis prevents 
progression to later asthma.
Neonatal WT and IRF7-/- mice were infected with PVM (2 pfu), treated with the RIPK1 
(Nec-1s) or MLKL inhibitor (GW80), then challenged with PVM (left hand panel in C-E) or 
cockroach allergen (right hand panel in C-E) in later life.
(A) Study design.
(B) Representative micrograph of Muc5ac (red; x200 magnification) and ASM staining (red; 
x100 magnification) in PVM/PVM infected IRF7-/- mice.
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(C) Quantification of Muc5ac positive cells.
(D) Quantification of ASM area.
(E) Eosinophils in BALF.
Data are representative of n = 2 experiments with three to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed using two-way ANOVA with Sidak’s post hoc test. *, P <0.05; **, P <0.01; 
***, P <0.001 are compared to untreated (diluent) WT or IRF7-/- infected mice. ##, P <0.01 is 
compared to Nec-1s treated WT or IRF7-/- infected mice.
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Figure 4
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Figure 5
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Figure 6
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Online Data Supplement 
RSV Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells 
Jennifer Simpson, Zhixuan Loh, Md Ashik Ullah, Jason P. Lynch, Rhiannon B. Werder, 
Natasha Collinson, Vivian Zhang, Yves Dondelinger, Mathieu J.M. Bertrand, Mark L. 
Everard, Christopher C. Blyth,  Gunter Hartel, Antoon J. Van Oosterhout, Peter J. Gough, 
John Bertin, John W. Upham, Kirsten M. Spann, Simon Phipps. 
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Materials and Methods. 
Human subjects and nasopharyngeal samples. 
Samples were prospectively collected from 2-year-old children (IQ range 1.25 to 3.86) 
presenting with acute respiratory infection to the Princess Margaret Hospital Emergency 
Department. Ethical approval for the study was obtained from the ethics committees of Princess 
Margaret Hospital for Children (1673/EP), the South Metropolitan Area Health Service, and 
the Western Australian Aboriginal Health Information and Ethics Committee. Bilateral mid 
turbinate nasal swabs were collected using flocked swabs (Copan Diagnostics Inc, Murrieta, 
CA). The swab was gently inserted into the nostril until resistance was felt. The swab was 
rotated several times against the nasal wall. On removal, swabs were inserted into a commercial 
viral transport media (UTMTM Viral Transport Media; Copan Diagnostics Inc, Murrieta, CA). 
All samples were frozen at -80oC prior to measurement of HMGB1 concentration using a 
commercially avilable ELISA (Chondrex, Redmond, WA, US). Nasopharyngeal samples were 
tested by polymerase chain reaction (PCR) assay for respiratory viruses. 
hAEC culture and treatment 
Human AECs from healthy paediatric (age 2-3 years) donors (ID 28195, 28563, 28385, and 
29055) were obtained commercially (Lonza). For all experiments, with the exception of 
Supplemental Figure E2, the cells were grown in a submerged culture system. In Supplemental 
Figure E2, the hAECs were differentiated at air-liquid interface (ALI) as previously described 
(1), and treated with NSA (10µM) or Nec-1s (2.2mM) for 1 hour prior to RSV infection. Cells 
were incubated with RSV A2 (MOI 1) for 4 hours, whereafter the inoculum was washed off 
and fresh media added. At 24 hpi, cells were fixed with neutral buffered 10% formalin solution 
(Sigma) for 15 minutes. Paraffin-embedded sections of the ALI membranes were prepared as 
previously described (1). 
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Bronchoalveolar lavage fluid (BALF) 
PBS was washed through the lungs using an adaptor inserted into the trachea. The solution was 
collected and centrifuged at 5000 rpm to separate cells and supernatant. The supernatant was 
stored at -20°C prior to quantification of cytokine production by ELISA or CBA. Cells were 
treated with Gey’s red blood cell lysis buffer to remove erythrocytes. The remaining leukocytes 
were counted using a haemocytometer and flow cytometry performed as described below.  
 
Flow cytometry 
Lung cells were mashed through a cell strainer and red blood cells lysed with Gey’s red blood 
cell lysis buffer. Cells were seeded into a U-bottom 96 well plate at 106/well, and pre-incubated 
with anti-FcRIII/II (‘Fc-block’) in PBS/1% FCS medium prior to a 30 minute incubation with 
one or more of the following fluorochrome-labelled antibodies (BD Biosciences unless 
otherwise stated). ILC2s defined as lineage-, ST2+, CD90.2+, CD25+. Eosinophils defined as 
SigF+, CD3-, B220-, MHCII- and neutrophils defined as CD3-, B220-, CD11b+, Ly6G+ 
Antibodies used: CD11c-FITC (Miltenyi), SiglecH-AF647, B220-V500, CD11b-PerCP Cy5.5. 
Ly6G-AF488, Siglec-F-APC, B220-PE, CD11b-PerCP Cy5.5, CD3-PE, MHCII-APC Cy7 
CD11c-FITC (Miltenyi), CD45R-AF488 (Miltenyi), CD3-AF488 (Miltenyi), CD11c-AF488 
(Miltenyi), CD2-AF488 (Miltenyi), Gr-1-AF488 (Miltenyi), CD11b-AF488 (Miltenyi), 
CD90.2-APC-Cy7 and CD25-BV650. After three washes in PBS/2% FCS medium cells were 
analysed using a BD LSR Fortessa x-20. 
 
Cytokine analysis  
The concentration of IL-33 (R & D systems, Minneapolis, MN, US), IL-5 (BD Biosciences, 
San Jose, CA, USA), eotaxin-2 (R & D systems, Minneapolis, MN, US) and HMGB1 
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(Chondrex, Redmond, WA, US) expression in BALF and/or lung homogenates was analysed 
by ELISA according to the manufacturer’s protocol. Cytokine bead array (CBA) was used to 
measure type 1 IFN, TNFα and IL-13 (BD) as per the manufacturer’s instructions. Double 
stranded (dsDNA; Invitrogen) was measured according to the manufacturer’s protocol. Lactate 
dehydrogenase (LDH; (Thermofisher) was measured according to the manufacturer’s protocol. 
Data is presented as percentage of the positive control provided in the kit.  
 
Immunohistochemistry and Immunofluorescence 
Paraffin-embedded sections were prepared as previously described (2). Slides were dehydrated 
using xylene and ethanol washes before antigen retrieval using citrate buffer. Lung sections 
were permeabilized using 0.5% Triton in PBS for 10 minutes. Non-specific binding was 
blocked with 10% normal goat serum in PBS. Primary antibodies used:anti-PVM (kindly 
provided by Dr Ulla Buchholz, Laboratory of Infectious Diseases, National Institute of Allergy 
and Infectious Diseases, 1:100), anti-HMGB1 (Abcam, ab18256; 1:400 dilution), anti-α-
smooth muscle actin (Sigma, clone 1A4; 1:800), anti-pRIPK1 (Ser166) (kindly provided by 
GSK; 1:450),  anti-MLKL (Merk Millipore, clone 3H1; 1:200), anti-cleaved caspase-3 (Asp 
175) conjugated-488 (CST, CST9669; 1:200). Mouse lung  were incubated overnight at room 
temperature with the primary antibody. For bright-field microscopy, sections were washed 3 
times in PBS/Tween 20 before 60 minutes of incubation with either anti-rabbit IgG- alkaline 
phosphatase (AP) (Sigma; 1:200), anti-mouse IgG-AP (Sigma; 1:200) or anti-rat IgG-AP 
(Sigma; 1:200). After washing, colour was developed with Fast Red substrate (Sigma). Sections 
were counterstained with hematoxylin before mounting with Glycergel (Dako). Quantitative 
analyses were conducted with Aperio Image Scope software (Aperio, Vista, Calif). Images were 
captured at ×20 or ×40 magnification with an Olympus microscope (model BX51), a digital 
camera (Olympus DP70), and DP software (Olympus, Center Valley, Pa). 
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For detection by immunofluorescence (pRIPK1, MLKL), slides were incubated at room 
temperature overnight as described above, washed with 0.5% Triton in PBS, then incubated 
with goat anti-rabbit-AF555 (Sigma; 1:500) and goat anti-rat 647 (Sigma; 1:500) respectively 
for 1 hour at room temperature. Slides stained with cleaved caspase-3-488 were not incubated 
with a secondary antibody. All slides were counterstained using DAPI (Sigma; 1:10,000), 
mounted with fluorescent mounting media (DAKO) and imaged on a Diskovery Spinning Disk 
confocal microscope (Nikon) or a Zeiss 780-NLO Point scanning confocal (Zeiss).   
 
To quantify PVM, HMGB1, MLKL and pRIPK1-positive AECs, the fraction of 
immunoreactive AECs was counted in a minimum of three airways, and the mean value for 
each mouse presented in the graph. To enumerate ASM area, Aperio IMageScope (Leica 
Biosystems Inc, IL, USA) software was used to measure the area (m2) of -smooth muscle 
actin immunoreactivity. The square root of this value was divided by the length of the basement 
membrane (m). For each mouse, three airways were counted and the mean value for each 
mouse presented in the graph, as described previously (3, 4).  
 
For immunofluorescent detection of antigens in hAECs, the cells were incubated with  anti-
human pMLKL (S358) (Abcam, ab187091; 1:200), anti-human pRIPK1 (Ser166; same clone 
as used on mouse tissue), anti-human cleaved caspase-3 (Asp 175) conjugated-488 (CST, 
CST9669; 1:200) and anti-human HMGB1 (R&D, MAB1690; 1:300). Secondary antibodies 
and other procedures were used as described above. For Propidium iodide (PI) (Thermofisher; 
1:1000) and annexin V (BD Biosciences, BD 550475; 1:200) staining, live cells were incubated 
for 10 or 30 minutes respectively before washing with distilled water and mounting as described 
above. Quantification for all antibodies consisted of determining the number of immunoreactive 
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cells as percentage of total cells. 100 to 300 cells were counted per data point, representing 
approximately 30% of the total cell count. 
 
Quantitative real time PCR 
Total RNA was isolated from the inferior right lung lobe with TriReagent solution (Ambion) 
followed by phenol-chloroform extraction. DNAse digestion was performed with Turbo 
DNAse (Ambion) as described previously (5). Reverse transcription was performed using M-
MLV reverse transcriptase and random primers (Invitrogen). qRT-PCR was performed with 
SYBR Green (Life Technologies). Primer sequences are shown in Table E1. Expression values 
were normalized relative to the housekeeping genes Hprt (mouse cells) or β-actin (human cells) 
and expressed as fold change relative to naïve (vehicle treated) mice of the same genotype using 
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Figure legends: 
Supplemental Figure E1: Inhibition of RIPK1 kinase activity or MLKL reduces viral 
load 
Submerged human AECs were were pre-treated with cell death inhibitors then infected with 
RSV (MOI of 1). Endpoints were assessed at 24 hours post infection. (A) Quantification of 
cleaved caspase-3 (CC3) and RSV positive cells. 
(B) RSV gene expression. 
(C) IFNλ2 gene and protein expression. 
(D) IFNλ1 and IFNλ3 gene expression. 
(E) IFNβ gene expression. 
Data are representative of n = 2 experiments with four donors in each group and are presented 
as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data were analyzed 
using one-way ANOVA with Dunnette’s post hoc test. *, P <0.05 and **, P <0.01 are 
compared to RSV-infected hAECs (A) or uninfected hAECs (B-E). #, P <0.05 and ##, P 
<0.01 are compared to MLKL-inhibitor treated RSV infected hAECs (A) or RSV-infected 
hAECs (B-E).  
 
Supplemental Figure E2: Inhibition of RIPK1 kinase activity or MLKL lowers viral 
load and HMGB1 translocation and release in differentiated AECs. 
Air-liquid interface-differentiated human AECs were infected with RSV (MOI 1). Expression 
of HMGB1, necroptosis proteins and cell death markers were assessed at 24 hours post 
infection.  (A) Expression of dsDNA in supernatant and Quantification of cleaved caspase-3 
(CC3) positive AECs. 
(B) Representative images (x200 magnification) of pRIPK1 and pMLKL (green). 
Quantification of pRIPK1 and pMLKL positive AECs. 
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(C) Quantification of cytoplasmic HMGB1 positive AECs. HMGB1 protein expression in 
basal supernatant. 
(D) Quantification of RSV positive AECs. 
Data are representative of n = 2 experiments with four donors in each group and are presented 
as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data were analyzed 
using one-way ANOVA with Dunnett’s post hoc test. *, P <0.05; **, P <0.01 and ***, P 
<0.001 are compared to uninfected hAECs. #, P <0.05 and ##, P <0.01 are compared to RSV-
infected hAECs.  
 
Supplemental Figure E3: Absence of IRF7 or high viral load predisposes to elevated cell 
death and necroptosis during acute viral infection.  
Neonatal WT and IRF7-/- mice were infected with PVM (2 or 100 pfu)at 7 days of age. 
Endpoints were assessed over time.  
(A) dsDNA, LDH and protein expression in bronchoalveolar lavage fluid (BALF). TNFα 
protein expression in lung.  
(B) Quantification of abnormal nuclei. Red is MLKL.  
(C) Representative micrograph (x400 magnification) of MLKL (green) and Phalloidin 
(cytoskeleton marker) (red). Quantification of apical MLKL positive AECs.  
(D) Representative micrograph (x400 magnification) of MLKL (red) and cleaved caspase-3 
(green) positive AECs. 
(E)  Representative micrograph (x400 magnification) of MLKL (red) and PVM (green) 
positive AECs. Quantification of MLKL expressing PVM-positive AECs. 
(F) Quantification of PVM and pRIPK1positive AECs. Quantification of PVM positive and 
pRIPK1 and MLKL double positive AECs.   
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Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers). Data 
were analyzed using two-way ANOVA with Sidak’s post hoc test (A), Student’s t test (B,C, 
E) or one-way ANOVA with Dunnett’s post hoc test. *, P <0.05; **, P <0.01; ***, P <0.001 
and ****, P<0.0001 are compared to PVM infected (2 pfu) WT mice. 
 
Supplemental Figure E4: Inhibition of RIPK1 kinase activity or MLKL alter cytokine 
expression during acute viral infection.  
Neonatal WT and IRF7-/- mice were treated with either a RIPK1 inhibitor (Nec-1s) or MLKL 
inhibitor (GW80) then infected with PVM (2 pfu) at 7 days of age. Expression of TNFα and 
IL-33 was determined at 10 days post infection. 
(A) TNFα protein expression in lung.  
(B) IL-33 protein expression in BALF.  
Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers; a–k). Data 
were analyzed using one-way ANOVA with Dunnett’s (A) or two-way (B) ANOVA with 
Sidak’s post hoc test.  **, P <0.01 is compared to untreated (diluent) WT or IRF7-/- infected 
mice. 
 
Supplemental Figure E5: Inhibition of pRIPK1 by GSK’963 reduces alarmin release, 
bronchiolitis, Th2 inflammation and airway remodelling.  
Neonatal WT and IRF7-/- mice were treated with a RIP1K inhibitor (GSK’963) then infected 
with PVM (2 pfu) at 7 days of age. Endpoints were assessed at 7 and 10 days post infection.  
(A) Study design.  
(B) Quantification of MLKL, cleaved caspase-3 (CC3) and AEC sloughing in AECs. 
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(C) Quantification of PVM positive AECs. 
(D) Quantification of cyto-HMGB1 and protein expression of HMGB1 and IL-33 in BALF. 
(E) ILC2 in lung. 
(F) Eosinophils in BALF. 
(G) Neutrophils in BALF. 
(H) Quantification of ASM area. 
Data are representative of n = 2 experiments with four to six neonates in each group and are 
presented as box-and-whisker plots showing quartiles (boxes) and range (whiskers; a–k). Data 
were analyzed using two-way ANOVA with Sidak’s post hoc test.*, P <0.05; **, P <0.01 and 
***, P <0.001 are compared to inactive enantiomer (control) treated WT or IRF7-/- infected 
mice. 
Supplemental Table E1: qPCR primers (Sigma) 
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Supplemental Figure 5
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Supplemental Table 1
Gene Forward Primer Reverse Primer
Mouse Casp3 TGAATCCACTGAGGTTTTGTTG TGCTGGTGGGATCAAAGC
Mouse Ripk1 CTCCAACACACCACTTTTGG CTCCAACACACCACTTTTGG
Mouse Ripk3 TCCCAATCTGCACTTCAGAAC GACACGGCACTCCTTGGTAT
Mouse Mlkl AGGAACCAGTGGGTCAGGAT CAAGATTCCGTCCACAGAGGG
Mouse Pvm G GCCTGCATCAACACAGTGTGT GCCTGATGTGGCAGTGCTT
Human RSV AAGGGATTTTTGCAGGATTGTTT CTCCCCACCGTAGCATTACTTG
Human IFNλ2 (IL28A) CTCTGTCACCTTCAACCTCTTC ATCTCAGGTTGCATGACTGG
Human IFNλ1 (IL-29) CTGACGCTGAAGGTTCTGG CTGACGCTGAAGGTTCTGG
Human IFNλ3 (IL-28B) CTGACGCTGAAGGTTCTGG ATATGGTGCAGGGTGTGAAG
Human IFNβ CTCTGGCAACAGGTAGTAGG GGAAAGAGCTGTAGTGGAGAAG
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